Fevipiprant

Drug Profile

Fevipiprant

Alternative Names: NVP-QAW-039; QAW-039

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Acetic acids; Anti-inflammatories; Antiallergics; Antiasthmatics; Pyridines; Pyrroles
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Allergic asthma
  • Phase II Atopic dermatitis
  • No development reported Allergic rhinitis

Most Recent Events

  • 03 Sep 2016 Efficacy and adverse events data from a phase II trial in Atopic asthma presented at the 26th Annual Congress of the European Respiratory Society (ACERS-2016)
  • 01 Dec 2015 Phase-III clinical trials in Allergic asthma (In adolescents, In adults, In elderly) in Canada, Netherlands, Slovakia and Spain (PO) (NCT02563067)
  • 01 Dec 2015 Phase-III clinical trials in Allergic asthma (In adolescents, In adults, In elderly) in USA, Austria, Estonia, Germany, Belgium, Hungary, Iceland and Latvia (PO) (NCT02555683)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top